At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 371 enrolled
Drug / intervention
Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution and Travoprost 0.004% (BAK-preserved) Eye Drops, Solution for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 371 participants.
Detailed Summary
A Multi-Center Double-masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-angle Glaucoma or Ocular Hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2009
Enrollment StartMar 2009
Primary CompletionJan 2010
TodayJul 2026
First PostedFeb 20, 2009
Enrollment StartMar 1, 2009
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.4 years ago
Interventions
Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solutiondrug
One drop once daily in the evening for 3 months
Travoprost 0.004% (BAK-preserved) Eye Drops, Solutiondrug
One drop once daily in the evening for 3 months